Approximately 230 million people around the world have Atopic Dermatitis, an ‘itchy’ skin condition characterised by remission and relapse, that can cause patients to have low self-esteem and can be very restrictive socially.
At Optimal we are dedicated to research in this area, with extensive capabilities, proven results and access to a large pool of patients.
We have access to a database of 1300 patients with Atopic Dermatitis who are interested in contributing to research, a database that is in constant growth.
- We have experience in commercial Phase 1b to 3 Atopic Dermatitis, for patients with moderate to severe disease.
- We are experts at dermatology rating scales including diagnosis using the Hanifin and Rajka Criteria, Investigator Global Assessment (IGA), and Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM) and 5-D pruritus.
- We have an in-house principal investigator Dr Penny Montgomery and experienced Dermatologist and Dermatopathologist Dr Nick Turnbull, as well as access to Auckland specialists.
Research capabilities and results
We also have:
- Experience in biologics.
- Contributed to trials for drugs which have now been FDA approved and marketed.
- A proven recruitment track record, achieving an average of three times the randomisation targets in the last eight Atopic Dermatitis trials.
- Been able to retain 89% of our participants across all therapeutic areas – compared with our competitors who retain less than 43%*.
At Optimal Clinical Trials, we exist to improve everyday lives for current and future patients in need. Our vision is a world where people live longer, healthier, happier lives. We do this by inspiring hope, aiding discoveries and contributing to knowledge, by providing outstanding research experiences. Discovery of greater solutions for people can only happen when you partner with passionate people – those who strive to innovate and create change. That’s why our research partners choose to work with us again and again.
About Atopic Dermatitis
Atopic Dermatitis, also called Atopic Eczema, the most common inflammatory skin disease worldwide, presents as generalised skin dryness and ‘the rash that itches’.
Approximately 230 million people around the world have it and the lifetime prevalence is >15%, especially in wealthier countries.
It usually starts in infancy, affecting up to 20% of children and approximately 80% of children affected develop it before the age of 6 years.
Although it can settle in late childhood and adolescence, the prevalence in young adults up to 26 years of age is still 5–15%.
It results from a complex interplay between environmental and genetic factors.
Credit: DermNet NZ